Nonsteroidal anti-inflammatory drugs versus placebo for post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis

Carregando...
Imagem de Miniatura
Citações na Scopus
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
GEORG THIEME VERLAG KG
Autor de Grupo de pesquisa
Citação
ENDOSCOPY INTERNATIONAL OPEN, v.7, n.4, p.E477-E486, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and study aims Endoscopic retrograde cholangiopancreatography (ERCP) is the primary therapeutic procedure for treatment of diseases that affect the biliary tree and pancreatic duct. While the therapeutic success rate of ERCP is high, the procedure can cause complications, such as acute pancreatitis (PEP), bleeding, and perforation. This meta-analysis aimed to assess the efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) in preventing PEP following (ERCP). Materials and methods We searched databases, such as MEDLINE, Embase, and Cochrane Central Library. Only randomized controlled trials (RCTs) that compared the efficacy of NSAIDs and placebo for the prevention of PEP were included. Outcomes assessed included incidence of PEP, severity of pancreatitis, route of administration, and type of NSAIDs. Results Twenty-one RCTs were considered eligible with a total of 6854 patients analyzed. Overall, 3427 patients used NSAIDs before ERCP and 3427 did not use the drugs (control group). In the end, 250 cases of acute pancreatitis post-ERCP were diagnosed in the NSAIDs group and 407 cases in the placebo group. Risk for PEP was lower in the NSAID group (risk difference (RD): -0.05; 95% confidence interval (CI): -0.07 to -0.03; number need to treat (NNT), 20; P<0.05). Use of NSAIDs effectively prevented mild pancreatitis compared with use of placebo (2.5% vs. 4.1%; 95% CI, -0.05 to -0.01; NNT, 33; P<0.05), but the information on moderate and severe PEP could not be completely elucidated. Only rectal administration reduced incidence of PEP (6.8% vs. 13 %; 95% CI, -0.10 to -0.04; NNT, 20; P<0.05). Furthermore, only diclofenac or indomethacin use was effective in preventing PEP. Conclusions Rectal administration of diclofenac and indomethacin significantly reduced risk of developing mild PEP. Further RCTs are needed to compare efficacy between NSAID administration pathways in prevention of PEP after ERCP.
Palavras-chave
Referências
  1. Bhatia V, 2011, J CLIN GASTROENTEROL, V45, P170, DOI 10.1097/MCG.0b013e3181eb600e
  2. BRUST R, 1977, GASTROINTEST ENDOSC, V24, P77, DOI 10.1016/S0016-5107(77)73457-1
  3. Chandrasekhara V, 2017, GASTROINTEST ENDOSC, V85, P32, DOI 10.1016/j.gie.2016.06.051
  4. Cheon YK, 2007, GASTROINTEST ENDOSC, V66, P1126, DOI 10.1016/j.gie.2007.04.012
  5. Choudhary A, 2011, GASTROINTEST ENDOSC, V73, P275, DOI 10.1016/j.gie.2010.10.039
  6. De Moura Eduardo T.H., 2016, Rev. gastroenterol. Perú, V36, P308
  7. Dobronte Z, 2014, WORLD J GASTROENTERO, V20, P10151, DOI 10.3748/wjg.v20.i29.10151
  8. Dumonceau JM, 2014, ENDOSCOPY, V46, P799, DOI 10.1055/s-0034-1377875
  9. Elmunzer BJ, 2012, NEW ENGL J MED, V366, P1414, DOI 10.1056/NEJMoa1111103
  10. Andrade-Davila VF, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0314-2
  11. Ferreira AD, 2015, ABCD-ARQ BRAS CIR DI, V28, P207, DOI 10.1590/S0102-67202015000300016
  12. Freeman ML, 2001, GASTROINTEST ENDOSC, V54, P425, DOI 10.1067/mge.2001.117550
  13. GUERRA M, 1967, J AMER MED ASSOC, V200, P552, DOI 10.1001/jama.200.6.552
  14. Hauser G, 2017, SURG ENDOSC, V31, P602, DOI 10.1007/s00464-016-5004-9
  15. Hosseini M, 2016, ARCH IRAN MED, V19, P538, DOI 0161908/AIM.004
  16. Hwang HJ, 2017, REV ESP ENFERM DIG, V109, P174, DOI 10.17235/reed.2017.4565/2016
  17. Ishiwatari H, 2016, DIGEST DIS SCI, V61, P3292, DOI 10.1007/s10620-016-4251-x
  18. Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
  19. Khoshbaten M, 2008, J GASTROEN HEPATOL, V23, pE11, DOI 10.1111/j.1440-1746.2007.05096.x
  20. Kubiliun NM, 2015, CLIN GASTROENTEROL H, V13, P1231, DOI 10.1016/j.cgh.2014.11.038
  21. Leerhoy B, 2016, SCAND J GASTROENTERO, V51, P1007, DOI 10.3109/00365521.2016.1172338
  22. Levenick JM, 2016, GASTROENTEROLOGY, V150, P911, DOI 10.1053/j.gastro.2015.12.040
  23. Li X, 2014, WORLD J GASTROENTERO, V20, P12322, DOI 10.3748/wjg.v20.i34.12322
  24. Loza AM, 2007, REV ESP ENFERM DIG, V99, P330
  25. Lua GW, 2015, DIGEST DIS SCI, V60, P3118, DOI 10.1007/s10620-015-3609-9
  26. Makela A, 1997, SCAND J CLIN LAB INV, V57, P401, DOI 10.3109/00365519709084587
  27. Mansour-Ghanaei F, 2016, WORLD J GASTROENTERO, V22, P5114, DOI 10.3748/wjg.v22.i21.5114
  28. Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097
  29. Murray B, 2003, GASTROENTEROLOGY, V124, P1786, DOI 10.1016/S0016-5085(03)00384-6
  30. Nesvaderani M, 2015, INT J SURG, V23, P68, DOI 10.1016/j.ijsu.2015.07.701
  31. OLAZABAL A, 1980, J LAB CLIN MED, V96, P570
  32. Onofrio FD, 2017, SURG ENDOSC, V31, P2317, DOI 10.1007/s00464-016-5234-x
  33. Otsuka T, 2012, J GASTROENTEROL, V47, P912, DOI 10.1007/s00535-012-0554-7
  34. Park SW, 2015, ENDOSCOPY, V47, P33, DOI 10.1055/s-0034-1390743
  35. Patai A, 2015, J CLIN GASTROENTEROL, V49, P429, DOI 10.1097/MCG.0000000000000168
  36. Sajid MS, 2015, WORLD J GASTRO ENDOS, V7, P1341, DOI 10.4253/wjge.v7.i19.1341
  37. Senol A, 2009, WORLD J GASTROENTERO, V15, P3999, DOI 10.3748/wjg.15.3999
  38. Shi N, 2015, TURK J GASTROENTEROL, V26, P236, DOI 10.5152/tjg.2015.6000
  39. Sun HL, 2014, SURG-J R COLL SURG E, V12, P141, DOI 10.1016/j.surge.2013.10.010
  40. Ucar R, 2016, TURK J MED SCI, V46, P1059, DOI 10.3906/sag-1502-104
  41. Vandervoort J, 2002, GASTROINTEST ENDOSC, V56, P652, DOI 10.1067/mge.2002.129086
  42. Yokoe M, 2015, J HEPATO-BIL-PAN SCI, V22, P405, DOI 10.1002/jhbp.259
  43. Zhao ZH, 2017, GASTROINTEST ENDOSC, V86, P519, DOI 10.1016/j.gie.2016.12.020